Paper Details

  1. Home
  2. Paper Details

Cardiovascular adverse events in multiple myeloma patients.

Author: DoroudgarShirin, HeckmannMarkus B, KatusHugo A, LehmannLorenz H

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Overview

This article reviews the clinical and preclinical data on approved proteasome inhibitors, such as bortezomib, carfilzomib, and ixazomib, used to treat multiple myeloma. The review focuses on the underlying pathomechanisms related to cardiovascular adverse events observed in clinical trials, highlighting the need for further research to understand and manage these side effects.
Paper Details　
Original Abstract of the Article :
Multiple myeloma is a malignant disease, caused by an uncontrolled clonal proliferation of a specific group of white blood cells, the plasma cells. Clinical manifestations include bone pain due to osteolysis, hypercalcemia, anemia, and renal insufficiency. Proteasome inhibitors have substantially im...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6328391/

データ提供：米国国立医学図書館（NLM）

Multiple Myeloma and Cardiovascular Risks: Unraveling the Connection

This study sheds light on the complex relationship between multiple myeloma, a type of blood cancer, and cardiovascular adverse events. The research investigates the potential risks associated with proteasome inhibitors, a class of drugs commonly used to treat multiple myeloma. The authors examine the preclinical and clinical data related to these inhibitors, specifically focusing on the mechanisms underlying cardiovascular complications in patients. This research is essential for understanding the potential risks and benefits of proteasome inhibitors in managing multiple myeloma.

Proteasome Inhibitors: A Double-Edged Sword in Multiple Myeloma Treatment?

While proteasome inhibitors have proven effective in treating multiple myeloma, this research highlights the potential for cardiovascular complications. The study underscores the importance of careful monitoring and management of cardiovascular health in patients receiving these treatments. This research serves as a reminder of the complex interplay between cancer treatment and overall patient health.

Navigating Multiple Myeloma Treatment: Balancing Benefits and Risks

It's crucial to understand the potential risks and benefits of any treatment, especially those involving powerful medications. This research provides valuable insights into the cardiovascular risks associated with proteasome inhibitors used in multiple myeloma therapy. It underscores the importance of open communication with healthcare providers to make informed decisions about treatment options and to manage potential side effects effectively.

Dr.Camel's Conclusion

This research sheds light on the cardiovascular risks associated with proteasome inhibitors used in multiple myeloma treatment. It underscores the importance of careful monitoring and management of cardiovascular health in patients receiving these treatments. The authors emphasize the need for continued research to better understand the mechanisms underlying these complications and to develop strategies for minimizing cardiovascular risks in patients with multiple myeloma.
Date :
  1. Date Completed n.d.
  2. Date Revised 2023-10-05
Further Info :

Pubmed ID

30701098

DOI: Digital Object Identifier

PMC6328391

Related Literature

Article Analysis
・Side Effects of ixazomib
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.